Tickertape - Financial freedom begins here

Sunrise Industrial Traders will hold a meeting of the Board of Directors of the Company on 3 May 2025.Powered by Capital Market - Live

Kranti Industries will hold a meeting of the Board of Directors of the Company on 29 April 2025.Powered by Capital Market - Live

ACC announced that the 89th Annual General Meeting(AGM) of the company will be held on 26 June 2025.Powered by Capital Market - Live

Mid East Portfolio Management announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 17 May 2025.Powered by Capital Market - Live

Fedbank Financial Services will hold a meeting of the Board of Directors of the Company on 29 April 2025.Powered by Capital Market - Live

Revenue from operations jumped 19.49% YoY to Rs 1,720.30 crore in Q4 FY25. Profit before tax (PBT) soared 191.17% to Rs 312.34 crore during the quarter ended 31st March 2025. EBITDA stood at Rs 477 crore in Q4 FY25, recording growth of 84%, as compared with Rs 259 crore in Q4 FY24. It includes one-time gain of Rs 59 crore from sale of land in 4Q FY25. EBITDA margin expanded to 27.7% in Q4 FY25 as against 18% in Q4 FY24. Revenue from CDMO segment jumped 85% to Rs 490 crore in Q4 FY25 as compared with Rs 265 crore in Q4 FY24. In Q4 FY25, revenue from small molecules jumped 95% YoY to Rs 461 crore, driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets. While revenue from Bio business remained flat YoY at Rs 29 crore during the quarter. Revenue from generics business rose 5% to Rs 1,230 crore during the quarter as compared with Rs 1,175 crore in Q4 FY24. Revenue from API business declined 8% YoY to Rs 686 crore in Q4 FY25, while revenue from Finished Dosages Form (FDF) climbed 27% YoY to Rs 544 crore during the quarter. The company said that multiple integrated CMO contract signed, supplies started. FDF manufacturing lines expansion on track ' coming online by Dec-25. 'Continued investments in growth projects with CAPEX at 12% of Revenue to support long term growth' the company stated in exchange filing. On financial year basis, the company's consolidated net profit surged 123.18% to Rs 358.32 crore in FY25 as compared with Rs 160.55 crore in FY24. Revenue from operations jumped 10.18% to Rs 5,553.96 crore in FY25 as against Rs 5,040.83 crore in FY24, driven by robust demand environment for the company's CDMO offering and higher FDF sales. Satyanarayana Chava, founder 'Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.' V V Ravi Kumar, executive director 'Despite the ongoing macroeconomic challenges, we have witnessed high level of demand for our offerings. For Q4, we delivered Rs 1,720 crore in revenues, growth of 19% and Rs 477 crore EBITDA grew by 84%, resulting in 27.7% margin. Gross margins remained healthy at 55% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy. Overall FY25 results, we have delivered revenues of Rs 5,554 crore, representing 10% growth and EBITDA stood at Rs 1,115 crore, growth of 40%. The EBITDA margin of 20.1% has substantially improved, supported by continuing operating leverage within CDMO business. Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritizing investments into high value business opportunities.' Meanwhile, the company's board approved a 2nd interim dividend of Rs 0.80 per share of Rs 2 each for FY25. The company has fixed May 09, 2025 as the record date for the said dividend. The amount will be paid on or after May 20, 2025. Laurus Labs is a research-driven pharmaceutical manufacturing organization, it has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. It has three business divisions Generics (API+FDF), CDMO (Synthesis) and Bio. The counter shed 0.51% to end at Rs 647.15 on the BSE.Powered by Capital Market - Live

However, total income dropped 35.66% YoY to Rs 24,169.41 crore in the quarter ended 31 March 2025. On a sequential basis, the company's net profit and revenue jumped by 47.69% and 30.34%, respectively, compared to Q3 FY25. The life insurer's net premium income declined 4.99% YoY to Rs 23,860.71 crore in Q4 FY25. However, the company reported a loss of Rs 1,040.83 crore from investments in the March quarter of FY25, compared to an investment income of Rs 10,811.70 crore in the same period of FY24. On a full-year basis, the company's net profit jumped by 27.43% to Rs 2,413.30 crore despite an 11.69% decline in total income to Rs 1,17,118.67 crore in FY25 over FY24. The company's net worth grew by 14% YoY to Rs 16,980 crore in FY25 as compared to Rs 14,910 crore recorded in FY24. SBI Life reported a robust solvency ratio of 1.96 as on 31 March 2025 as against the regulatory requirement of 1.50 indicating strong financial position of the company. Assets under management (AuM) grew by 15% YoY to Rs 4,48,040 crore as of 31 March 2025, with a debt-equity mix of 61:39. Over 94% of the debt investments are in AAA and sovereign instruments. Value of new business (VoNB) increased by 7% YoY to Rs 5,950 crore for FY25. VoNB margin reduced to 27.8% in FY25 as against 28.1% recorded in FY24. New business premium (NBP) slipped 7% YoY to Rs 35,580 crore in FY25. Gross written premium (GWP) grew 4% to 84,980 crore in FY25, mainly due to 11% growth in new business regular premium (RP) and 14% growth in renewal premium (RP) in FY25. The company's total cost ratio for FY25 was at 9.7% as compared with 8.9% reported in FY24. The commission ratio was at 4.4% in FY25 as against 4% in FY24. Operating expense ratio for FY25 was 5.3% as against 4.9% in FY24. Annualized premium equivalent (APE) stood at Rs 21,420 crore, registering growth of 9% YoY. SBI Life recorded strong growth in 13th-month and 61st-month persistency (based on premium considering regular premium/limited premium payment under the individual category) in FY25 by 63 bps and 528 bps respectively, due to our focus on improving the quality of business and customer retention. SBI Life Insurance Company is carrying on the business of life insurance. The company's life insurance business comprises individual life and group business, including participating, non-participating, pension, group gratuity, group leave encashment, group superannuation, group immediate annuity, unit-linked insurance products, variable insurance products, health, and microinsurance. Some of these policies have riders such as accident and disability benefit, level term, and critical illness. Powered by Capital Market - Live

ACC announced that the Board of Directors of the Company at its meeting held on 24 April 2025, inter alia, have recommended the final dividend of Rs 7.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Elecon Engineering Company announced that the Board of Directors of the Company at its meeting held on 24 April 2025, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 150%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Kirloskar Pneumatic Company announced that the Board of Directors of the Company at its meeting held on 24 April 2025, inter alia, have recommended the final dividend of Rs 6.5 per equity Share (i.e. 325%) , subject to the approval of the shareholders.Powered by Capital Market - Live